OrbiMed led the $61.8m Series B financing round in Sparrow Pharmaceuticals.

Synopsis

OrbiMed, a global healthcare investment firm, led the $61.8m Series B financing round in Sparrow Pharmaceuticals, a Portland-based clinical-stage biopharmaceutical company developing therapies for conditions of corticosteroid excess, with participation from RiverVest Venture Partners, US Venture Partners, and Thomvest Ventures.

Principals

target

Sparrow Pharmaceuticals

bidder

Orbimed Pe

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context

Sort

Seller Team (1)

david katz

CEO at SPARROW PHARMACEUTICALS

Manager

target

Deal

£ 45 M

Total Value

Bidder Team (3)

jonathan silverstein

President at ORBIMED PE

Investor

bidder

Deals

£ 1.58 B

Total Value

jay schmelter

Managing Director at RIVERVEST VENTURE PARTNERS

Investor

bidder

Deals

£ 132 M

Total Value

casey tansey

General Partner at US VENTURE PARTNERS (USVP)

Investor

bidder

Deals

£ 182 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy